Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Medical Genetics

Biology and Genetics

At a Glance

AOMS4 is an inherited metabolic syndrome usually linked to a disease-causing change in the LRP6 gene. That change can disrupt cell signals controlling fat storage and blood sugar. Diagnosis uses genetic testing plus clinical findings, and one affected parent may pass the variant to each child.

The biology of Abdominal Obesity-Metabolic Syndrome 4 (AOMS4) is centered on a breakdown in how your cells communicate. While most people’s bodies manage fat and sugar through a combination of many genes, AOMS4 is a monogenic condition—meaning a single “misspelling” in one gene is powerful enough to drive the entire syndrome [1][2].

The Core Biological Mechanism: Wnt Signaling

AOMS4 is primarily linked to variations in the LRP6 gene [3][4]. This gene provides instructions for making a protein that sits on the surface of your cells and acts as a “docking station” for the Wnt signaling pathway [4].

Think of the Wnt pathway as a master switchboard that tells your cells what to become. In a healthy body, this pathway helps regulate:

  • Adipogenesis: The process of creating new fat cells.
  • Lipogenesis: How the body stores fat.
  • Glucose Metabolism: How cells respond to insulin and process sugar [5][6].

In AOMS4, a missense variant (a type of genetic change where one “letter” in the DNA code is swapped for another) can cause the LRP6 protein to change shape [7][8]. Researchers hypothesize this prevents the Wnt signal from being “plugged in” correctly. When this signal is weak or broken, the body may incorrectly process fat and become resistant to insulin [3][5]. Note that not every missense variant changes protein shape or disrupts signaling; effects depend on the exact variant.

Inheritance: The Autosomal Dominant Pattern

AOMS4 follows an autosomal dominant inheritance pattern. This is a crucial concept for understanding why the condition runs so strongly in some families [9][10].

  • Autosomal: The gene is located on one of the numbered chromosomes, not the sex chromosomes (X or Y). This means it affects men and women equally.
  • Dominant: You only need one copy of the altered gene to inherit the condition. Every person has two copies of the LRP6 gene (one from each parent). If you have AOMS4, one copy is working normally, but the other has a variant that “dominates” the instruction process [9][11].

If a parent has a confirmed pathogenic variant, there is a 50% chance with each pregnancy that the variant will be passed on to their child [10]. However, penetrance varies, so inheriting a variant does not mean a child will definitely develop severe disease.

Confirming the Diagnosis

Because AOMS4 looks so much like common obesity and diabetes, it cannot be diagnosed by physical exam alone. Doctors typically use a multigene panel (which looks at several genes related to metabolic syndrome, such as LRP6 and DYRK1B) or Whole Exome Sequencing (WES), which reads all the protein-coding parts of your DNA, alongside clinical correlation [12][13]. Genetic sequencing is not by itself a definitive diagnosis.

Your Genetic Report Checklist

When you receive your genetic report, interpret it with a genetics professional. Look for these specific details:

  1. Gene Name: It should specify LRP6 (for AOMS4) or DYRK1B (for the closely related AOMS3) [3][10].
  2. Variant Classification: A diagnosis generally requires a Pathogenic or Likely Pathogenic variant. A “Variant of Uncertain Significance” (VUS) means the lab isn’t sure yet if the change causes disease. A VUS must not guide predictive testing or treatment [14].
  3. Zygosity: For AOMS4, this will typically say Heterozygous, meaning you have one affected copy and one normal copy [9][11].
  4. Protein Change: This often looks like a code (e.g., p.Arg611Cys). This tells the doctor exactly which part of the LRP6 protein is altered [15].

A negative panel does not exclude all genetic causes. Also, a genetics specialist can determine whether a particular variant has a documented dental or skeletal phenotype, as specific LRP6 variants are sometimes linked to oligodontia (missing permanent teeth) or unusually high bone density [9][16][17].

Common questions in this guide

What gene is usually linked to AOMS4?
AOMS4 is primarily linked to disease-causing variants in LRP6, which makes a cell-surface protein involved in Wnt signaling. DYRK1B is associated with the related AOMS3, not the usual gene for AOMS4. A genetics professional should interpret the result alongside your clinical findings.
How is AOMS4 passed through families?
AOMS4 usually follows an autosomal dominant pattern, meaning one altered copy of the relevant gene can be enough to cause the condition. If a parent has a confirmed pathogenic variant, each pregnancy has a 50% chance of inheriting it. The severity of disease can vary, so inheriting the variant does not guarantee severe features.
What genetic tests are used to diagnose AOMS4?
Doctors may use a multigene panel that includes LRP6 or whole-exome sequencing. Results are not definitive on their own and must be considered with clinical findings, and a negative panel does not rule out every genetic cause. Ask whether deletion and duplication analysis was included if only sequence testing was performed.
What does a variant of uncertain significance mean on an AOMS4 report?
A variant of uncertain significance is a DNA change whose role in disease is not yet known. It should not be used by itself to guide predictive testing or treatment decisions. Review the result with a genetics professional.
What does heterozygous mean in an AOMS4 genetic report?
Heterozygous means that one copy of the relevant gene carries the variant and the other copy does not. This fits the usual autosomal dominant pattern, but the severity of features can vary among people who inherit the variant.
Can an LRP6 variant affect teeth or bone?
Some specific LRP6 variants have been linked to oligodontia, meaning missing permanent teeth, or unusually high bone density. These features are not established for every variant, so ask a genetics specialist whether your exact change has a documented association.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on abdominal obesity-metabolic syndrome 4.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my genetic report identify a 'pathogenic' or 'likely pathogenic' variant in the LRP6 or DYRK1B gene?
  2. 2.Since my condition is inherited in an autosomal dominant pattern, which of my relatives should be referred for genetic counseling?
  3. 3.How does an LRP6 variant affect my specific risk for heart disease or high bone mass compared to standard metabolic syndrome?
  4. 4.Is my variant a 'missense variant,' and what does the laboratory say about its effect on the Wnt signaling pathway?
  5. 5.Can we review the 'Zygosity' section of my report to confirm if I have one (heterozygous) or two (homozygous) copies of this variant?

References

References (17)
  1. 1

    The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits.

    Hinney A, Körner A, Fischer-Posovszky P

    Nature reviews. Endocrinology 2022; (18(10)):623-637 doi:10.1038/s41574-022-00716-0.

    PMID: 35902734
  2. 2

    Genetics and epigenetics in obesity.

    Rohde K, Keller M, la Cour Poulsen L, et al.

    Metabolism: clinical and experimental 2019; (92()):37-50 doi:10.1016/j.metabol.2018.10.007.

    PMID: 30399374
  3. 3

    Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis.

    Go GW

    Nutrients 2015; (7(6)):4453-64 doi:10.3390/nu7064453.

    PMID: 26046396
  4. 4

    The association of LRP6 rs2302685 (V1062I) polymorphism with the risk of hyperlipidemia in Iranian children and adolescents.

    Montazeri-Najafabady N, Dabbaghmanesh MH, Mohammadian Amiri R

    Annals of human genetics 2018; (82(6)):382-388 doi:10.1111/ahg.12254.

    PMID: 30039844
  5. 5

    Therapeutic Targeting of LRP6 in Cardiovascular Diseases: Challenging But Not Wnt-Possible!

    Labbé P, Thorin E

    The Canadian journal of cardiology 2019; (35(11)):1567-1575 doi:10.1016/j.cjca.2019.06.030.

    PMID: 31679626
  6. 6

    Toosendanin inhibits adipogenesis by activating Wnt/β-catenin signaling.

    Chen TX, Cheng XY, Wang Y, Yin W

    Scientific reports 2018; (8(1)):4626 doi:10.1038/s41598-018-22873-x.

    PMID: 29545541
  7. 7

    Extracellular LDLR repeats modulate Wnt signaling activity by promoting LRP6 receptor endocytosis mediated by the Itch E3 ubiquitin ligase.

    Vijayakumar S, Liu G, Wen HC, et al.

    Genes & cancer 2017; (8(7-8)):613-627 doi:10.18632/genesandcancer.146.

    PMID: 28966723
  8. 8

    Novel Mutation of LRP6 Identified in Chinese Han Population Links Canonical WNT Signaling to Neural Tube Defects.

    Shi Z, Yang X, Li BB, et al.

    Birth defects research 2018; (110(1)):63-71 doi:10.1002/bdr2.1122.

    PMID: 28960852
  9. 9

    LRP6 β-Propeller Destabilization: Novel Variant, Phenotype and Diagnostic Implications in Tooth Agenesis.

    Intarak N, Ghasemnejad T, Fakhruddin KS, et al.

    International dental journal 2026; (76(2)):109367 doi:10.1016/j.identj.2025.109367.

    PMID: 41505923
  10. 10

    Two novel variants in DYRK1B causative of AOMS3: expanding the clinical spectrum.

    Mendoza-Caamal EC, Barajas-Olmos F, Mirzaeicheshmeh E, et al.

    Orphanet journal of rare diseases 2021; (16(1)):291 doi:10.1186/s13023-021-01924-z.

    PMID: 34193236
  11. 11

    A novel missense mutation of LRP6 identified by whole-exome sequencing in a Chinese family with non-syndromic tooth agenesis.

    Wang H, Liu Y, Zheng Y, et al.

    Orthodontics & craniofacial research 2021; (24(2)):233-240 doi:10.1111/ocr.12424.

    PMID: 32844563
  12. 12

    A targeted next-generation sequencing assay for the molecular diagnosis of genetic disorders with orodental involvement.

    Prasad MK, Geoffroy V, Vicaire S, et al.

    Journal of medical genetics 2016; (53(2)):98-110 doi:10.1136/jmedgenet-2015-103302.

    PMID: 26502894
  13. 13

    Expanding the genetic spectrum of tooth agenesis using whole-exome sequencing.

    Yu K, Dou J, Huang W, et al.

    Clinical genetics 2022; (102(6)):503-516 doi:10.1111/cge.14225.

    PMID: 36071541
  14. 14

    Whole-Exome Sequencing Identifies Novel Variants for Tooth Agenesis.

    Dinckan N, Du R, Petty LE, et al.

    Journal of dental research 2018; (97(1)):49-59 doi:10.1177/0022034517724149.

    PMID: 28813618
  15. 15

    The interplay of canonical and noncanonical Wnt signaling in metabolic syndrome.

    Abou Ziki MD, Mani A

    Nutrition research (New York, N.Y.) 2019; (70()):18-25 doi:10.1016/j.nutres.2018.06.009.

    PMID: 30049588
  16. 16

    Rare phenotype: Hand preaxial polydactyly associated with LRP6-related tooth agenesis in humans.

    Zhang L, Yu M, Sun K, et al.

    NPJ genomic medicine 2021; (6(1)):93 doi:10.1038/s41525-021-00262-0.

    PMID: 34759310
  17. 17

    Novel variant in LRP6 associated with unusual and severe clinical presentation: Case report.

    Previdi A, Dubourg C, Cormier Daire V, et al.

    Clinical genetics 2024; (105(6)):666-670 doi:10.1111/cge.14501.

    PMID: 38385987

This page explains AOMS4 biology, inheritance, and genetic testing for informational purposes only and does not constitute medical advice. A genetics professional should interpret your report and discuss testing for relatives.